Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | CAL-101 | 1 | 72 | 1.0 | 5741.0 | 6240.0 | 1443.3 | 0.0 | 0.923 | 0.920 | 2.112 | BT20 CAL101 0 1 |
| BT-549 | TGX221 | 1 | 72 | 1.0 | 4645.8 | 5515.0 | 1554.9 | 0.0 | 0.821 | 0.842 | 1.826 | BT549 TGX221 0 1 72 |
| BT-20 | PIK-93 | 1 | 72 | 1.0 | 4892.3 | 5875.8 | 1443.3 | 0.0 | 0.827 | 0.833 | 2.025 | BT20 PIK93 0 1 |
| BT-20 | CAL-101 | 2 | 72 | 1.0 | 3064.8 | 3469.3 | 1018.6 | 0.0 | 0.865 | 0.883 | 1.768 | BT20 CAL101 0 2 |
| BT-20 | Omipalisib | 2 | 72 | 1.0 | 235.0 | 3349.0 | 1018.6 | 0.0 | -0.574 | 0.070 | 1.717 | BT20 GSK458 0 2 |
| BT-20 | ZSTK474 | 3 | 72 | 1.0 | 982.5 | 3579.5 | 586.9 | 0.0 | 0.218 | 0.274 | 2.609 | BT20 ZSTK474 0 3 |
| BT-20 | Everolimus | 3 | 72 | 1.0 | 1644.5 | 3144.8 | 586.9 | 0.0 | 0.530 | 0.523 | 2.422 | BT20 Everolimus 0 3 |
| BT-20 | GDC-0980 | 2 | 72 | 1.0 | 611.3 | 3217.8 | 1018.6 | 0.0 | -0.265 | 0.190 | 1.659 | BT20 GDC0980 0 2 |
| BT-20 | Trametinib | 3 | 72 | 1.0 | 2177.5 | 3410.0 | 586.9 | 0.0 | 0.676 | 0.639 | 2.539 | BT20 Trametinib 0 3 |
| BT-549 | Torin2 | 1 | 72 | 1.0 | 1265.8 | 5306.0 | 1554.9 | 0.0 | -0.110 | 0.239 | 1.771 | BT549 Torin2 0 1 72 |
| BT-549 | Trametinib | 1 | 72 | 1.0 | 3762.8 | 5460.3 | 1554.9 | 0.0 | 0.629 | 0.689 | 1.812 | BT549 Trametinib 0 1 72 |
| BT-20 | Everolimus | 2 | 72 | 1.0 | 1591.0 | 3213.5 | 1018.6 | 0.0 | 0.309 | 0.495 | 1.658 | BT20 Everolimus 0 2 |
| BT-549 | ZSTK474 | 1 | 72 | 1.0 | 2875.0 | 5649.0 | 1554.9 | 0.0 | 0.391 | 0.509 | 1.861 | BT549 ZSTK474 0 1 72 |
| BT-20 | WYE-125132 | 3 | 72 | 1.0 | 807.3 | 3344.0 | 586.9 | 0.0 | 0.135 | 0.241 | 2.510 | BT20 WYE125132 0 3 |
| BT-549 | XL147 | 1 | 72 | 1.0 | 5410.8 | 5624.3 | 1554.9 | 0.0 | 0.959 | 0.962 | 1.855 | BT549 XL147 0 1 72 |
| BT-549 | Torin1 | 3 | 72 | 1.0 | 1230.0 | 3974.5 | 1175.8 | 0.0 | 0.026 | 0.309 | 1.757 | BT549 Torin1 0 3 72 |
| BT-549 | WYE-125132 | 3 | 72 | 1.0 | 1367.3 | 3719.8 | 1175.8 | 0.0 | 0.095 | 0.368 | 1.662 | BT549 WYE125132 0 3 72 |
| BT-20 | WYE-125132 | 2 | 72 | 1.0 | 847.0 | 3613.5 | 1018.6 | 0.0 | -0.096 | 0.234 | 1.827 | BT20 WYE125132 0 2 |
| BT-20 | Sirolimus | 1 | 72 | 1.0 | 3619.3 | 5856.5 | 1443.3 | 0.0 | 0.576 | 0.618 | 2.021 | BT20 Rapamycin 0 1 |
| BT-20 | Pictilisib | 2 | 72 | 1.0 | 1217.8 | 3416.0 | 1018.6 | 0.0 | 0.108 | 0.356 | 1.746 | BT20 GDC0941 0 2 |
| BT-20 | PIK-93 | 2 | 72 | 1.0 | 2226.5 | 3542.3 | 1018.6 | 0.0 | 0.545 | 0.629 | 1.798 | BT20 PIK93 0 2 |
| BT-20 | CAL-101 | 3 | 72 | 1.0 | 3187.5 | 3531.5 | 586.9 | 0.0 | 0.922 | 0.903 | 2.589 | BT20 CAL101 0 3 |
| BT-20 | XL147 | 2 | 72 | 1.0 | 3330.0 | 3509.0 | 1018.6 | 0.0 | 0.942 | 0.949 | 1.784 | BT20 XL147 0 2 |
| HCC70 | GDC-0980 | 3 | 72 | 1.0 | 1244.3 | 2773.8 | 517.3 | 0.0 | 0.437 | 0.449 | 2.423 | HCC70 GDC0980 0 3 72 |
| HCC70 | Pictilisib | 3 | 72 | 1.0 | 1619.0 | 2827.0 | 517.3 | 0.0 | 0.593 | 0.573 | 2.450 | HCC70 GDC0941 0 3 72 |